PCRX logo

Pacira BioSciences (PCRX)

Profile

Full Name

Pacira BioSciences, Inc.

Ticker Symbol

PCRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

February 3, 2011

Indexes

Not included

Website

http://www.pacira.com

Employees

788

Key Details

Price

$24.65(+0.74%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$700.97M(+3.85% YoY)

Annual EPS

-$2.15(-341.57% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$24.65
PCRX price is $24.65

30-Day Relative Volume

0.44
PCRX 30-day relative volume is 0.44

Price Performance

Price Most recent change

+0.74%
PCRX price was up +0.74% on Apr 17, 2025

Price YTD change

+30.84%
PCRX price is up +30.84% since January 1st

Price 1-year change

-7.92%
PCRX price is down -7.92% year-on-year

Price 3-year change

-66.99%
PCRX price is down -66.99% over the past 3 years

Price Range

Price All-time high

$121.95
PCRX price is currently -79.79% below its historical high of $121.95

Price 3-year low

$11.16
PCRX price is currently +120.88% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$1.14B
PCRX market capitalization is $1.14 billion

Market cap 3-year change

-66.31%
PCRX market capitalization is down -66.31% over the past 3 years

Market cap All-time high

$4.32B
PCRX market capitalization is currently -73.61% below its historical high of $4.32 billion

Market cap sector rank

77.86%
PCRX market capitalization is higher than 77.86% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-0.52%
PCRX shares outstanding is down -0.52% year-on-year

Shares Outstanding 3-Year Change

+2.08%
PCRX shares outstanding is up +2.08% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.29
PCRX beta is 0.29

200-day SMA

$19.72
PCRX price is currently +24.99% above its 200-day simple moving average

50-day SMA

$24.62
PCRX price is currently +0.10% above its 50-day simple moving average

RSI

51.22
PCRX 14-day relative strength index is 51.22

Volume

0.44
PCRX 30-day relative volume is 0.44

ATR

$1.37
PCRX average true range is $1.37

10-day Historical Volatility

96.20%
PCRX 10-day historical volatility is 96.20%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$700.97M
PCRX annual revenue is $700.97 million

Revenue Analysts estimate

$752.94M
PCRX annual revenue is currently -6.90% lower than the consensus analysts' forecast

Revenue 1-year change

+3.85%
PCRX annual revenue is up +3.85% year-on-year

Revenue Sector rank

77.47%
PCRX annual revenue is higher than 77.47% of companies in Healthcare sector

EPS

EPS

-$2.15
PCRX annual earnings per share is -$2.15

EPS Analysts estimate

$2.90
PCRX annual earnings per share is currently -174.09% lower than the consensus analysts' forecast

EPS 1-year change

-341.57%
PCRX annual earnings per share is down -341.57% year-on-year

EPS Sector rank

37.2%
PCRX annual earnings per share is higher than 37.2% of companies in Healthcare sector

Profit

Gross profit

$530.54M
PCRX annual gross profit is $530.54 million

Gross margin

75.69%
PCRX annual gross profit margin is 75.69%

Operating profit

$97.57M
PCRX annual operating income is $97.57 million

Operating margin

13.92%
PCRX annual operating profit margin is 13.92%

Net income

-$99.56M
PCRX annual net profit is -$99.56 million

Net margin

-14.20%
PCRX annual net profit margin is -14.20%

Expenses

Total expenses

$603.39M
PCRX annual total expenses is $603.39 million

Operating expenses

$432.96M
PCRX annual total operating expenses is $432.96 million

Cost of goods sold

$170.43M
PCRX annual cost of goods sold is $170.43 million

Selling, general & administrative expenses

$294.10M
PCRX annual SGA is $294.10 million

Depreciation and amortization

$78.78M
PCRX annual depreciation & amortization is $78.78 million

Interest expense

$13.44M
PCRX annual interest expense is $13.44 million

Income tax

$36.45M
PCRX annual income tax is $36.45 million

EBIT & EBITDA

EBIT

-$49.67M
PCRX annual earnings before interest & taxes is -$49.67 million

EBITDA

$29.12M
PCRX annual EBITDA is $29.12 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.55B
PCRX annual total assets is $1.55 billion

Non current assets

$808.39M
PCRX annual long term assets is $808.39 million

Current assets

$745.13M
PCRX annual total current assets is $745.13 million

Cash and cash equivalents

$276.77M
PCRX annual cash & cash equivalents is $276.77 million

Accounts receivable

$113.30M
PCRX annual accounts receivable is $113.30 million

Inventory

$125.28M
PCRX annual inventory is $125.28 million

Liabilities

Total liabilities

$775.17M
PCRX annual total liabilities is $775.17 million

Long term liabilities

$465.25M
PCRX annual total long term liabilities is $465.25 million

Current liabilities

$309.92M
PCRX annual total current liabilities is $309.92 million

Accounts payable

$19.13M
PCRX annual accounts payable is $19.13 million

Debt

Total debt

$638.85M
PCRX annual total debt is $638.85 million

Total debt 1-year change

+9.01%
PCRX annual total debt is up +9.01% year-on-year

Long term debt

$428.19M
PCRX annual long term debt is $428.19 million

Short term debt

$210.66M
PCRX annual short term debt is $210.66 million

Equity & Capital

Shareholders equity

$778.35M
PCRX annual stockholders equity is $778.35 million

Book value

$778.35M
PCRX annual book value is $778.35 million

Retained earnings

-$206.36M
PCRX annual retained earnings is -$206.36 million

Working capital

$435.21M
PCRX annual working capital is $435.21 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$189.39M
PCRX annual cash flow from operations is $189.39 million

Cash from operations 1-year change

+22.46%
PCRX annual cash flow from operations is up +22.46% year-on-year

Cash from investing

-$83.28M
PCRX annual cash flow from investing activities is -$83.28 million

Cash from investing 1-year change

-207.4%
PCRX annual cash flow from investing activities is down -207.4% year-on-year

Cash from financing

$17.36M
PCRX annual cash flow from financing activities is $17.36 million

Cash from financing 1-year change

+109.49%
PCRX annual cash flow from financing activities is up +109.49% year-on-year

CAPEX

CAPEX

$10.64M
PCRX annual capital expenditures is $10.64 million

CAPEX 1-year change

-29.85%
PCRX annual capital expenditures is down -29.85% year-on-year

Free Cash Flow

Free cash flow

$178.75M
PCRX annual free cash flow is $178.75 million

Free cash flow 1-year change

+28.15%
PCRX annual free cash flow is up +28.15% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

75.69%
PCRX annual gross profit margin is 75.69%

Operating margin

13.92%
PCRX annual operating profit margin is 13.92%

Net margin

-14.20%
PCRX annual net profit margin is -14.20%

ROA & ROE

ROA

-6.37%
PCRX annual return on assets is -6.37%

ROE

-12.08%
PCRX annual return on equity is -12.08%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
PCRX price to earnings ratio value is unknown

PE ratio Sector rank

-
PCRX price to earnings ratio is unknown

PB Ratio

PB ratio

1.47
PCRX price to book ratio is 1.47

PB ratio Sector rank

55.56%
PCRX price to book ratio is higher than 55.56% of companies in Healthcare sector

PS Ratio

PS ratio

1.63
PCRX price to sales ratio is 1.63

PS ratio Sector rank

38.25%
PCRX price to sales ratio is higher than 38.25% of companies in Healthcare sector

Enterprise value

Enterprise value

$1.50B
PCRX enterprise value is $1.50 billion

Enterprise value Sector rank

79.17%
PCRX enterprise value is higher than 79.17% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

51.61
PCRX EV/EBITDA is 51.61

EV/EBITDA Sector rank

97.39%
PCRX EV/EBITDA is higher than 97.39% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.40
PCRX annual current ratio is 2.40

Quick ratio

2.00
PCRX annual quick ratio is 2.00

Leverage

Debt to equity

0.75
PCRX annual debt to equity ratio is 0.75

Interest coverage ratio

-3.70
PCRX annual interest coverage ratio is -3.70

Risk & Stability

Piotroski F-Score

5
PCRX piotroski f-score is 5

Altman Z-Score

1.38
PCRX altman z-score is 1.38

Analyst ratings

Recent major analysts updates

Apr 8, 25 Needham
Buy
Apr 8, 25 HC Wainwright & Co.
Buy
Feb 28, 25 Needham
Buy
Feb 28, 25 HC Wainwright & Co.
Buy
Feb 28, 25 Barclays
Overweight
Jan 30, 25 Truist Securities
Hold
Jan 14, 25 RBC Capital
Sector Perform
Jan 13, 25 Needham
Buy
Dec 17, 24 Needham
Buy
Dec 4, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

INVA logo
Innoviva (INVA)
ARDX logo
Ardelyx (ARDX)
AZTA logo
Azenta (AZTA)
Indivior (INDV)
TNDM logo
Tandem Diabetes Care (TNDM)
OCUL logo
Ocular Therapeutix (OCUL)
Kestra Medical Technologies (KMTS)
AMPH logo
Amphastar Pharmaceuticals (AMPH)
LQDA logo
Liquidia (LQDA)
  • What is the ticker symbol for Pacira BioSciences?
  • Does Pacira BioSciences pay dividends?
  • What sector is Pacira BioSciences in?
  • What industry is Pacira BioSciences in?
  • What country is Pacira BioSciences based in?
  • When did Pacira BioSciences go public?
  • Is Pacira BioSciences in the S&P 500?
  • Is Pacira BioSciences in the NASDAQ 100?
  • Is Pacira BioSciences in the Dow Jones?
  • When was Pacira BioSciences's last earnings report?
  • When does Pacira BioSciences report earnings?
  • Should I buy Pacira BioSciences stock now?

What is the ticker symbol for Pacira BioSciences?

The ticker symbol for Pacira BioSciences is NASDAQ:PCRX

Does Pacira BioSciences pay dividends?

No, Pacira BioSciences does not pay dividends

What sector is Pacira BioSciences in?

Pacira BioSciences is in the Healthcare sector

What industry is Pacira BioSciences in?

Pacira BioSciences is in the Drug Manufacturers - Specialty & Generic industry

What country is Pacira BioSciences based in?

Pacira BioSciences is headquartered in United States

When did Pacira BioSciences go public?

Pacira BioSciences's initial public offering (IPO) was on February 3, 2011

Is Pacira BioSciences in the S&P 500?

No, Pacira BioSciences is not included in the S&P 500 index

Is Pacira BioSciences in the NASDAQ 100?

No, Pacira BioSciences is not included in the NASDAQ 100 index

Is Pacira BioSciences in the Dow Jones?

No, Pacira BioSciences is not included in the Dow Jones index

When was Pacira BioSciences's last earnings report?

Pacira BioSciences's most recent earnings report was on Feb 27, 2025

When does Pacira BioSciences report earnings?

The next expected earnings date for Pacira BioSciences is May 7, 2025

Should I buy Pacira BioSciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page